Anacetrapib, an CETP (cholesteryl ester transfer protein) inhibitor that was developed for increasing HDL cholesterol levels and promoting CEC to a greater degree, was shown a significant reduction in CAD in the REVEAL trial (38). Here, CETP is linked to coronary artery disorder.